Clinical Trial

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-05-13; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT06979531
Lead Sponsor Immunovant Sciences GmbH
Conditions Primary Sjögren's Syndrome
Enrollment 180 participants
Start Date 2025-06-30
Primary Completion 2028-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-12